Investigational Drug Information for UGN-102
✉ Email this page to a colleague
What is the drug development status for UGN-102?
UGN-102 is an investigational drug.
There have been 4 clinical trials for UGN-102.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.
The most common disease conditions in clinical trials are Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, and Carcinoma. The leading clinical trial sponsors are UroGen Pharma Ltd. and [disabled in preview].
There are five hundred and forty-one US patents protecting this investigational drug and zero international patents.
Summary for UGN-102
| US Patents | 541 |
| International Patents | 35,060 |
| US Patent Applications | 4,553 |
| WIPO Patent Applications | 2,819 |
| Japanese Patent Applications | 98 |
| Clinical Trial Progress | Phase 2 (2021-11-01) |
| Vendors | 45 |
Recent Clinical Trials for UGN-102
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | UroGen Pharma Ltd. | Phase 3 |
| A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
Clinical Trial Summary for UGN-102
Top disease conditions for UGN-102
Top clinical trial sponsors for UGN-102
US Patents for UGN-102
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| UGN-102 | ⤷ Sign Up | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | ⤷ Sign Up |
| UGN-102 | ⤷ Sign Up | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) | ⤷ Sign Up |
| UGN-102 | ⤷ Sign Up | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for UGN-102
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| UGN-102 | Australia | AU2006269422 | 2025-07-07 | ⤷ Sign Up |
| UGN-102 | Canada | CA2614436 | 2025-07-07 | ⤷ Sign Up |
| UGN-102 | European Patent Office | EP1917020 | 2025-07-07 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
